GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Sale Of Investment

BeiGene (BSP:B1GN34) Sale Of Investment : R$1,456 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BeiGene Sale Of Investment?

BeiGene's sale of investment for the three months ended in Mar. 2024 was R$13 Mil. It means BeiGene gained R$13 Mil from selling investments. BeiGene's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was R$1,456 Mil.

Compared with last quarter (R$518 Mil in Dec. 2023 ), BeiGene gained less money from selling investments in Mar. 2024 (R$13 Mil).


BeiGene Sale Of Investment Historical Data

The historical data trend for BeiGene's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Sale Of Investment Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,724.98 14,153.46 17,795.35 8,201.80 3,298.74

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,963.44 924.81 0.09 518.01 13.22

BeiGene Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,456 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeiGene Sale Of Investment Related Terms

Thank you for viewing the detailed overview of BeiGene's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (BSP:B1GN34) Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines